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 We read with interest the paper by Azengruber and colleagues recently 
published in the journal. The authors reported significant variation among the 
different recombinant concentrates in terms of content of soluble protein 
aggregates and subvisible particles(1). This could be important in explaining the 
differential immunogenicity, in terms of inhibitor development, among 
recombinant concentrates. 
We were, however, disappointed that the authors do not name the nine brands of 
recombinant FVIII concentrates they studied. By convention in scientific 
literature, authors are required to name their reagents and their source. We can 
not see any reason why the names of the concentrates were withheld and invite 
the authors to name the products now. This is particularly relevant as the studies 
cited by Anzengruber et al to demonstrate the different rates of inhibitor 
incidence relative to product type do cite the products used (2), (3). A similar 
level of disclosure would have enhanced the relevance of Anzengrubǯs 
study and contributed to guiding therapeutic choice. 
Without naming the products, all one can conclude is that there is variation 
between the products but by naming them the scientific community can 
correlate the results with other observations about specific concentrates. We 
note that, in order to differentiate their particular products and leverage market 
advantage, some products are acquiring approval from regulatory agencies by 
validating conditions, including storage at room temperature (4), which may 
well precipitate the kind of environmental pressure which generates the changes 
reported by Anzengruber et al (5). It would seem that the kind of analytes 
studied in their paper should be considered for the purpose of product quality 
control, but for this to be considered by authorities full information is required. 
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